Cargando…

The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs

Tuberculosis (TB) poses an enduring threat to global health. Consistently ranked among the top 10 causes of death worldwide since 2000, TB has now exceeded HIV-AIDS in terms of deaths inflicted by a single infectious agent. In spite of recently declining TB incident rates, these decreases have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Huan, Nyantakyi, Samuel A., Li, Ming, Gopal, Pooja, Aziz, Dinah B., Yang, Tianming, Moreira, Wilfried, Gengenbacher, Martin, Dick, Thomas, Go, Mei L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060259/
https://www.ncbi.nlm.nih.gov/pubmed/30072978
http://dx.doi.org/10.3389/fmicb.2018.01627
_version_ 1783342000519512064
author Chen, Huan
Nyantakyi, Samuel A.
Li, Ming
Gopal, Pooja
Aziz, Dinah B.
Yang, Tianming
Moreira, Wilfried
Gengenbacher, Martin
Dick, Thomas
Go, Mei L.
author_facet Chen, Huan
Nyantakyi, Samuel A.
Li, Ming
Gopal, Pooja
Aziz, Dinah B.
Yang, Tianming
Moreira, Wilfried
Gengenbacher, Martin
Dick, Thomas
Go, Mei L.
author_sort Chen, Huan
collection PubMed
description Tuberculosis (TB) poses an enduring threat to global health. Consistently ranked among the top 10 causes of death worldwide since 2000, TB has now exceeded HIV-AIDS in terms of deaths inflicted by a single infectious agent. In spite of recently declining TB incident rates, these decreases have been incremental and fall short of threshold levels required to end the global TB epidemic. As in other infectious diseases, the emergence of resistant organisms poses a major impediment to effective TB control. Resistance in mycobacteria may evolve from genetic mutations in target genes which are transmitted during cell multiplication from mother cells to their progeny. A more insidious form of resistance involves sub-populations of non-growing (“dormant”) mycobacterial persisters. Quiescent and genetically identical to their susceptible counterparts, persisters exhibit non-inheritable drug tolerance. Their prevalence account for the protracted treatment period that is required for the treatment of TB. In order to improve the efficacy of treatment against mycobacterial persisters and drug-resistant organisms, novel antitubercular agents are urgently required. Selective targeting of bacterial membranes has been proposed as a viable therapeutic strategy against infectious diseases. The underpinning rationale is that a functionally intact cell membrane is vital for both replicating and dormant bacteria. Perturbing the membrane would thus disrupt a multitude of embedded targets with lethal pleiotropic consequences, besides limiting the emergence of resistant strains. There is growing interest in exploring small molecules as selective disruptors of the mycobacterial membrane. In this review, we examined the recent literature on different chemotypes with membrane perturbing properties, the mechanisms by which they induce membrane disruption and their potential as anti-TB agents. Cationic amphiphilicity is a signature motif that is required of membrane targeting agents but adherence to this broad physical requirement does not necessarily translate to conformity in terms of biological outcomes. Nor does it ensure selective targeting of mycobacterial membranes. These are unresolved issues that require further investigation.
format Online
Article
Text
id pubmed-6060259
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60602592018-08-02 The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs Chen, Huan Nyantakyi, Samuel A. Li, Ming Gopal, Pooja Aziz, Dinah B. Yang, Tianming Moreira, Wilfried Gengenbacher, Martin Dick, Thomas Go, Mei L. Front Microbiol Microbiology Tuberculosis (TB) poses an enduring threat to global health. Consistently ranked among the top 10 causes of death worldwide since 2000, TB has now exceeded HIV-AIDS in terms of deaths inflicted by a single infectious agent. In spite of recently declining TB incident rates, these decreases have been incremental and fall short of threshold levels required to end the global TB epidemic. As in other infectious diseases, the emergence of resistant organisms poses a major impediment to effective TB control. Resistance in mycobacteria may evolve from genetic mutations in target genes which are transmitted during cell multiplication from mother cells to their progeny. A more insidious form of resistance involves sub-populations of non-growing (“dormant”) mycobacterial persisters. Quiescent and genetically identical to their susceptible counterparts, persisters exhibit non-inheritable drug tolerance. Their prevalence account for the protracted treatment period that is required for the treatment of TB. In order to improve the efficacy of treatment against mycobacterial persisters and drug-resistant organisms, novel antitubercular agents are urgently required. Selective targeting of bacterial membranes has been proposed as a viable therapeutic strategy against infectious diseases. The underpinning rationale is that a functionally intact cell membrane is vital for both replicating and dormant bacteria. Perturbing the membrane would thus disrupt a multitude of embedded targets with lethal pleiotropic consequences, besides limiting the emergence of resistant strains. There is growing interest in exploring small molecules as selective disruptors of the mycobacterial membrane. In this review, we examined the recent literature on different chemotypes with membrane perturbing properties, the mechanisms by which they induce membrane disruption and their potential as anti-TB agents. Cationic amphiphilicity is a signature motif that is required of membrane targeting agents but adherence to this broad physical requirement does not necessarily translate to conformity in terms of biological outcomes. Nor does it ensure selective targeting of mycobacterial membranes. These are unresolved issues that require further investigation. Frontiers Media S.A. 2018-07-19 /pmc/articles/PMC6060259/ /pubmed/30072978 http://dx.doi.org/10.3389/fmicb.2018.01627 Text en Copyright © 2018 Chen, Nyantakyi, Li, Gopal, Aziz, Yang, Moreira, Gengenbacher, Dick and Go. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Chen, Huan
Nyantakyi, Samuel A.
Li, Ming
Gopal, Pooja
Aziz, Dinah B.
Yang, Tianming
Moreira, Wilfried
Gengenbacher, Martin
Dick, Thomas
Go, Mei L.
The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs
title The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs
title_full The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs
title_fullStr The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs
title_full_unstemmed The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs
title_short The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs
title_sort mycobacterial membrane: a novel target space for anti-tubercular drugs
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060259/
https://www.ncbi.nlm.nih.gov/pubmed/30072978
http://dx.doi.org/10.3389/fmicb.2018.01627
work_keys_str_mv AT chenhuan themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT nyantakyisamuela themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT liming themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT gopalpooja themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT azizdinahb themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT yangtianming themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT moreirawilfried themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT gengenbachermartin themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT dickthomas themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT gomeil themycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT chenhuan mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT nyantakyisamuela mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT liming mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT gopalpooja mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT azizdinahb mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT yangtianming mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT moreirawilfried mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT gengenbachermartin mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT dickthomas mycobacterialmembraneanoveltargetspaceforantituberculardrugs
AT gomeil mycobacterialmembraneanoveltargetspaceforantituberculardrugs